Research Papers:

Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy

Gang Li, Jieping Hu and Yuanjie Niu _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:217-223. https://doi.org/10.18632/oncotarget.18563

Metrics: PDF 1355 views  |   HTML 2855 views  |   ?  


Gang Li1,*, Jieping Hu2,* and Yuanjie Niu1

1Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China

2Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China

*These authors contributed equally to this work

Correspondence to:

Yuanjie Niu, email: [email protected]

Keywords: squamous differentiation, pT1, bladder cancer, urothelial carcinoma, intravesical chemotherapy

Received: October 31, 2016     Accepted: June 02, 2017     Published: June 19, 2017


The role of squamous differentiation in pT1 bladder tumors in the response to intravesical chemotherapy was unknown. We performed a retrospective analysis of 213 pT1 bladder urothelial carcinoma patients with squamous differentiation (group1), the remaining 213 pT1 pure urothelial carcinoma served as controls (group2). All cases were treated with transurethral resection of bladder tumor and subsequent intravesical chemotherapy. Within a five-year period, the tumor recurrence rate was 75.1% (160/213) in group 1 and 64.3% (137/213) in group 2. Tumor grade (HR = 2.926, P = 0.014), number of tumors (HR = 2.130, P = 0.038), tumor size (HR = 2.748, P = 0.031), and squamous differentiation (HR = 3.726, P = 0.019) were found to be important prognostic factors. Subgroup analysis for high grade tumors was performed, finding that group 1 had higher recurrence rate (50.3% vs 36.3%; for group 2). Progression was found in 32.2% (30/160) of group1 and 15.1% (11/137) of group2 (P = 0.011). Our data suggests that squamous differentiation is a predictor of poor response for intravesical chemotherapy, and that early radical cystectomy should be performed for high grade tumors, especially when dealing with recurrent cases.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18563